We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Hepatitis C Positive Antibody Test Leads to Molecular Assay

By LabMedica International staff writers
Posted on 18 Jan 2016
Image: Histopathology of chronic viral hepatitis C, necrosis and inflammation are prominent (Photo courtesy of University of Utah).
Image: Histopathology of chronic viral hepatitis C, necrosis and inflammation are prominent (Photo courtesy of University of Utah).
Conventional laboratory and medical practice for Hepatitis C virus infection involves referring a patient for a second office visit and blood draw if the initial antibody screening test produces a positive result.

A hepatitis C screening test identifies viral antibodies while a molecular test identifies viral ribonucleic acid (RNA) when the infection is active. In some people, the immune system clears hepatitis C infection on its own, but antibodies may linger in the blood for decades. As a result, a positive antibody screening test can signify resolved or active infection, and as much as 3% of antibody screens produce a false positive.

Quest Diagnostics (Madison, NJ, USA) will automatically perform molecular testing on all patient specimens whose antibody screening results indicate Hepatitis C virus infection, and remove standalone positive antibody screening as a test option. The change to the company’s service menu eliminates the prospect a patient may receive a positive screening result but fail to undergo additional molecular testing, as recommended by medical guidelines, to help confirm a diagnosis of active hepatitis C infection, the cause of chronic hepatitis C.

With the change to the Quest menu, any specimen that an antibody screening test indicates is positive will automatically reflex to molecular testing. Pricing for the screen and molecular tests are the same as before; positive screening results will reflex to molecular testing automatically and be charged the additional molecular test fee. Early diagnosis, through laboratory blood tests, and treatment can help prevent liver damage, cirrhosis, liver cancer and death.

Rick L. Pesano, MD, PhD, vice president of development, science and innovation at Quest Diagnostics, said, “This change to Quest's test offerings is medically responsible and appropriate. It closes a gap in current hepatitis C care by reducing the possibility a patient will undergo multiple office visits and blood draws or be inappropriately referred to specialists based on incomplete testing. With this change to our offering, we will help more people receive insights they can use to access effective treatment and ultimately lead healthier lives.”

Related Links:

Quest Diagnostics 


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Electrolyte Analyzer
CBS-4000 (CBS-400)
All-in-One Molecular System
AIO M160

Channels

Molecular Diagnostics

view channel
Image: The blood-based assay captures circulating chromatin, cell-free DNA fragments that are largely inaccessible through standard laboratory methods (image credit: Shuttertstock)

Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response

Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read more

Immunology

view channel
Image: New research shows that autoimmunity drives debilitating long COVID symptoms in a subset of patients (Image credit: Shutterstock)

Study Points to Autoimmune Pathway Behind Long COVID Symptoms

Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more

Industry

view channel
Image: Through the collaboration with SouthGenetics, healthcare professionals across Latin America and the Caribbean will gain access to C2N’s Precivity portfolio of blood tests

Partnership Expands Access to Alzheimer’s Blood Tests in Latin America and Caribbean

Alzheimer’s disease assessment remains challenging in many regions where aging populations are increasing demand for care, but access to dementia specialists and advanced imaging remains limited.... Read more
ADLM